Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15 avr. 2024 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
10 avr. 2024 13h47 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
04 avr. 2024 16h00 HE
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb
03 avr. 2024 03h10 HE
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy Market is...
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
13 mars 2024 16h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 mars 2024 16h05 HE
|
Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
11 mars 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
11 mars 2024 08h15 HE
|
Napigen, Inc.
The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.
CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
08 mars 2024 14h39 HE
|
Pairwise
Durham, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- The panel “The First CRISPR Foods Have Arrived” at this year’s SXSW Conference included leading agricultural scientists, researchers, and innovation...
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
05 mars 2024 16h30 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...